Cambridge, MA, United States of America

Gabriel Grant Gamber

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 8.1

ph-index = 4

Forward Citations = 80(Granted Patents)


Location History:

  • Marlborough, MA (US) (2016 - 2020)
  • Cambridge, MA (US) (2018 - 2022)

Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
11 patents (USPTO):

Title: Gabriel Grant Gamber: Innovator in Lipid Delivery Systems

Introduction

Gabriel Grant Gamber is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of lipid compositions for the delivery of active agents. With a total of 11 patents to his name, Gamber's work is at the forefront of pharmaceutical innovation.

Latest Patents

Gamber's latest patents focus on lipids and lipid compositions that enhance the delivery of biologically active agents. One of his notable inventions provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R-R, L, n, and p are defined. These compounds are cationic lipids that are instrumental in delivering biologically active agents to cells and tissues. His work in this area is crucial for advancing therapeutic applications.

Career Highlights

Gamber is currently associated with Novartis AG, a leading global healthcare company. His role involves researching and developing innovative lipid-based delivery systems that can improve the efficacy of various treatments. His expertise in this niche has positioned him as a key player in the pharmaceutical industry.

Collaborations

Gamber has collaborated with several talented individuals in his field, including Thomas Zabawa and Luis Brito. These collaborations have fostered a creative environment that encourages the development of groundbreaking solutions in lipid delivery.

Conclusion

Gabriel Grant Gamber's contributions to lipid compositions and their applications in drug delivery are noteworthy. His innovative spirit and dedication to research continue to drive advancements in the pharmaceutical sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…